Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Dulaglutide is a once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite6668, SS-31 improves mitochondrial bioenergetics, reduces oxidative stress, and shows protective effects in models of ischemia-reperfusion, neurodegeneration, and other mitochondrial disorders4637137.
While Dulaglutide works as a recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation66, SS-31 is a mitochondria-targeted tetrapeptide, d-Arg-dimethylTyr-Lys-Phe-NH2, that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, improving electron transport, and reducing ROS production4637137143.
Dulaglutide
GCG
SS-31
Not assigned in the current dataset.
Dulaglutide and SS-31 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Dulaglutide is more often discussed in the realm of Metabolic and endocrine, whereas SS-31 is more often associated with the realm of Aging and longevity and Cardiovascular health. They also influence different molecular systems, with Dulaglutide tracking more closely to GLP-1 receptor while SS-31 centers more on Mitochondrial membrane. Dulaglutide has a more engineered peptide origin, while SS-31 is closer to synthetic design background and their development context also differs, with Dulaglutide approved while SS-31 is in Clinical phase 2. Dulaglutide takes the form of a peptide conjugate, whereas SS-31 is closer to a linear peptide, SS-31 incorporates d-amino acid substitution and amidation features that are not part of Dulaglutide; while their sequence patterns also diverge, with Dulaglutide showing alpha-helical domain features and SS-31 showing cationic amphipathic features.